u87-mg cl-0238  (Procell Inc)

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: High ANGPT2 expression correlates with GBM progression and poorer prognosis. (A) ANGPT2 mRNA expression in different malignant tumors ( http://gepia.cancer-pku.cn/ ). (B) Comparison of ANGPT2 mRNA expression between normal brain and GBM tissues from TCGA datasets. (C) ANGPT2 mRNA expression in brain tumor at different stages ( http://www.cgga.org.cn/ ), # p < 0.001. (D) ANGPT2 mRNA expression in brain tumor at WHO stage IV in individuals of different gender and age ( http://www.cgga.org.cn/ ). (E) Kaplan-Meier curves estimating overall survival and (F) disease-free survival ( https://smuonco.shinyapps.io/PanCanSurvPlot ) in patients of ANGPT2 mRNA in GBM. Log-rank test, p < 0.001. (G) The observation of ANGPT2 protein expression in different stages of brain tumor tissues. (H) Representative images of ANGPT2 protein expression (a, c, e, and g, magnification 5 × ; b, d, f, and h, magnification 200 × , bar = 50 μm). (I) Positive rate of ANGPT2 in glioma in different stages of brain tumor tissues. (J, K) ANGPT2 expression was analyzed using IB in HA, T98G, U251, and U87-MG cells. ANGPT2 expression was quantified (ANGPT2/β-actin). Normalized ANGPT2 in HA cells was set at 1.0. ∗ p < 0.05, ∗∗ p < 0.01 ( n = 3). (L, M) ANGPT2 levels in membrane proteins were analyzed using IB in T98G, U251, and U87-MG cells. The level of ANGPT2 was quantified (ANGPT2/Na + -K + ATPase). IB, immunoblotting; HA, human astrocyte cell.

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Expressing, Comparison, Membrane, Western Blot

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: ANGPT2 promoted apoptosis and inhibited viability and Tie-2/Akt/Foxo-1 pathway in U87-MG cells. (A, B) IF staining with ANGPT2 antibody in different glioma cells and transfected U87-MG cells; DAPI staining shows nucleoli (magnification, 400 × , bar = 50 μm). (C–G) U87-MG cells were transfected with ANGPT2-siRNA or overexpressed plasmid pEX-3-ANGPT2 for 48 h. (C) Apoptosis percentage was analyzed using flow cytometry; ∗∗ p < 0.01, # p < 0.001 ( n = 3). (D) Cell cycle was analyzed using flow cytometry; ∗ p < 0.05, ∗∗ p < 0.01, # p < 0.001 ( n = 3). (E) Cell viability was measured using CCK-8 assay; ∗ p < 0.05, ∗∗ p < 0.01 ( n = 3). (F) Colony formation was observed and (G) calculated; ∗ p < 0.05, ∗∗ p < 0.01 ( n = 3). (H–K) NC and transfected U87-MG cells were seeded into transwell chambers. (H) Cell invasion in the lower chamber was observed (magnification, 200 × , bar = 50 μm) and (I) the number of cells was counted; ∗ p < 0.05 ( n = 3). (J) Cell migration in the lower chamber was observed (magnification, 200 × , bar = 50 μm) and (K) the number of cells was counted; ∗ p < 0.05 ( n = 3). (L–P) U87-MG cells were transfected with ANGPT2-siRNA or pEX-3-ANGPT2 for 48 h. (L) Analysis of ANGPT2 interaction with Tie-2 for co-IP assays with Tie-2 antibody. (M, O) Protein levels were detected using IB. Protein expression was quantified (target protein/β-actin) and normalized target protein in NC or vector cells was set to 1.0 (N, P); ∗ p < 0.05, ∗∗ p < 0.01, # p < 0.001 ( n = 3). IB, immunoblotting; IP, immunoprecipitation; co-IP, co-immunoprecipitation; IF, immunofluorescence.

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Staining, Transfection, Plasmid Preparation, Flow Cytometry, CCK-8 Assay, Migration, Co-Immunoprecipitation Assay, Expressing, Western Blot, Immunoprecipitation, Immunofluorescence

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: Targeting peptide uptake in U87-MG cells. (A, B) GSF and HSV effects on U87-MG cells, bEND.3 cells, and HUVECs. (C) Uptake process of FITC-labeled GSF and HSV in U87-MG cells co-cultivated with bEND.3 cells and HUVECs. (D) Flow cytometry analysis of FITC-labeled GSF and HSV uptake in U87-MG cells. (E) Immunofluorescence analysis of FITC-labeled GSF and HSV uptake in U87-MG cells; DAPI staining shows nucleoli (magnification, 400 × , bar = 50 μm). (F, G) Fluorescence intensity of FITC-labeled GSF and HSV in U87-MG cells. # p < 0.001 was calculated using ANOVA ( n = 6). (H) Micro-PET/CT imaging analysis of 68 Ga-DOTA-GSF/HSV in mouse brain with U87-MG cell xenograft. Micro-PET/CT imaging reconstruction was performed using PMOD software. (I) 68 Ga-DOTA-GSF/HSV biodistribution in the main organs was measured based on gamma counts ( n = 3 ). (J) 68 Ga-DOTA-GSF/HSV biodistribution in the brain was measured based on gamma counts; # p < 0.001 was calculated using ANOVA ( n = 3 ).

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Labeling, Flow Cytometry, Immunofluorescence, Staining, Fluorescence, Micro-PET, Imaging, Software

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: Targeting liposome characterization. (A) Mean particle size of targeting liposome-Dox. (B) PDI of targeting liposome-Dox. (C) Zeta potential of targeting liposome-Dox. (D, E) Morphology of targeting liposome-Dox was observed using TEM. (F) Fluorescence intensity of liposome-Dox based on ultraviolet absorption. (G–J) Effects of Dox, Lipo@Dox, and targeting liposome-Dox on U87-MG cells, bEND.3 cells, and HUVECs. (K, L) Immunofluorescence analysis of Cy5.5 for targeting liposome-Dox uptake in U87-MG cells co-cultivated with bEND.3 cells and HUVECs.

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Zeta Potential Analyzer, Fluorescence, Immunofluorescence

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: Targeting liposome-Dox uptake and glioma imaging. (A) Immunofluorescence analysis of Dox uptake in U87-MG cells co-cultivated with bEND.3 cells and HUVECs; DAPI staining shows nucleoli (magnification, 400 × , bar = 50 μm). (B, C) Mean fluorescence intensity was measured using image J; ∗ p < 0.05, # p < 0.001 ( n = 6). (D, E) Dox fluorescence intensity flow cytometry results for U87-MG cells co-cultivated with bEnd.3 cells and HUVECs. (F) Micro-PET/CT imaging analysis of 68 Ga-DOTA-GSF/HSV-Lipo@Dox in mouse brain with U87-MG cell xenograft and micro-PET/CT imaging reconstruction were performed using PMOD software. (G) 68 Ga-DOTA-GSF/HSV-Lipo@Dox biodistribution in main organs was measured based on gamma counts ( n = 2 ). (H) 68 Ga-DOTA-GSF/HSV-Lipo@Dox biodistribution in the brain was measured based on gamma counts, ∗∗ p < 0.01 ( n = 2 ).

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Imaging, Immunofluorescence, Staining, Fluorescence, Flow Cytometry, Micro-PET, Software

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: Targeting liposome-Dox inhibited U87-MG cells via Tie-2/Akt/Foxo-1 pathway. (A) Apoptotic ratio for U87-MG cells treated with liposome-Dox for 24 h, ∗ p < 0.05 ( n = 3). (B–D) Protein levels were detected using IB and protein expression was quantified (target protein/β-actin). (E, F) Colony formation was observed and calculated; ∗ p < 0.05 ( n = 3). (G–J) U87-MG cells were seeded into Transwell chambers and treated with 1 μg/mL of Dox (effective liposome-Dox concentration) for 24 h. (G) Cell migration in the lower chamber was observed (magnification, 200 × , bar = 50 μm) and (H) the number of cells was quantified; ∗ p < 0.05, ∗∗ p < 0.01 ( n = 3). (I) Cell invasion in the lower chamber was observed (magnification, 200 × , bar = 50 μm) and (J) the number of cells was determined; ∗ p < 0.05, ∗∗ p < 0.01 ( n = 3).

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Expressing, Concentration Assay, Migration

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: In vivo anti-glioma effect of targeting liposome-Dox. (A) Liposome-Dox (5 mg/kg of effective Dox concentration) delivered via intracranial injection into orthotropic U87-MG cell glioma model mice and observed at different time points. (B) Distribution of Cy5.5-labeled targeting liposome-Dox at different time points in mice. (C) Fluorescence intensity observed in the head at different time points. (D) Fluorescence of brain and organs 30 h after injection. (E) Liposome-Dox (2.5 mg/kg of effective Dox concentration) delivered via intracranial injection into orthotropic U87-MG cell xenograft model and observed at different time points. (F) BLI of orthotopic U87-MG-luc cell xenograft model at different time points. (G) Fluorescence intensity of orthotopic U87-MG-luc cell xenograft, n = 5. (H) MRI of orthotopic U87-MG-luc cell xenograft at different time points in mice. (I) Comparation for volume of orthotopic U87-MG-luc cell xenograft at different time points in mice, n = 5. (J) Body weight of tumor-bearing mice at different time points, n = 5. (K) Survival rate after treatment.

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: In Vivo, Concentration Assay, Injection, Labeling, Fluorescence

Journal: Materials Today Bio

Article Title: Doxorubicin-loaded PEGylated liposome modified with ANGPT2-specific peptide for integrative glioma-targeted imaging and therapy

doi: 10.1016/j.mtbio.2025.101455

Figure Lengend Snippet: Histological observation results for anti-tumor effect of targeting liposome-Dox. (A) H&E staining of orthotopic glioma. (B) TUNEL detection of apoptotic tumor cells; black arrows represent apoptotic tumor cells. (C) Immunofluorescence results for Ki-67 expression. (D) H&E staining analysis of toxicological effect of targeting liposome-Dox in different organs. (E) The BUN levels in plasma of orthotopic U87-MG-luc cell xenograft model after treatment, ∗ p < 0.05 ( n = 3). (F) The CREA levels in plasma of orthotopic U87-MG-luc cell xenograft model after treatment, ∗ p < 0.05 ( n = 3). (G) The UA levels in plasma of orthotopic U87-MG-luc cell xenograft model after treatment, ∗ p < 0.05 ( n = 3). (H) Target peptide-modified Lipo@Dox treatment inhibited U87-MG cell survival by inhibiting the Akt/GSK3β/β-catenin pathway. Lipo@Dox target peptide modification showed better suppression of glioma development than Lipo@Dox.

Article Snippet: U251 (The human malignant glioma cell lines, no. CL-0237) (Procell, China), HA (The human astrocyte cell lines, no.1800) (ScienCell Research Laboratories, San Diego, CA, USA), U87-MG (The human malignant glioma cell lines, no. CL-0238) (Procell, China), U87-MG-luc (The human astrocyte tumors cell line, no. WZ0028) (Fenghui Bio, Changsha, China) and bEND.3 (The mouse brain-derived endothelial cells.3, no. TCM-C715) (Hycyte Biotechnology, Suzhou, China) were cultured in DMEM medium with 10 % fetal bovine serum.

Techniques: Staining, TUNEL Assay, Immunofluorescence, Expressing, Modification

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: Effects of miR-9-3p overexpression on the proliferation of U87 cells. U87 cells were transfected with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (A and C) RT-qPCR was applied to quantify the expression level of miR-9-3p in U87 MG and TG-905 cells. (B and D) The cell viability of U87 cells was determined by a CCK-8 assay in U87 MG and TG-905 cells. ##P<0.01 vs. NC mimic group. miR-9-3p, microRNA-9-3p; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NC, negative control; control, without any treatment.

Article Snippet: Cell culture and transfection The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Over Expression, Transfection, Quantitative RT-PCR, Expressing, CCK-8 Assay, Real-time Polymerase Chain Reaction, Negative Control

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: Effects of miR-9-3p overexpression on the apoptosis of U87 cells. U87 cells were transfected with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (A) Annexin-V/PI double-staining assay was applied to detect the cell apoptotic rate in U87 MG cells. (B) Annexin-V/PI double-staining assay was applied to detect the cell apoptotic rate in TG-905 cells. ##P<0.01 vs. NC mimic group. miR-9-3p, microRNA-9-3p; NC, negative control; PI, propidium iodide; control, without any treatment.

Article Snippet: Cell culture and transfection The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Over Expression, Transfection, Double Staining, Negative Control

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: FOXG1 is a direct target of miR-9-3p in glioma cells. (A) Bioinformatics analysis of the predicted interactions of miR-9-3p and its binding sites within the 3′-UTR of FOXG1. (B) Relative luciferase activities of FOXG1-wt, and FOXG1-mut were identified using a Dual-Luciferase Reporter assay kit following transfection of U87 MG with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (C) The expression level of FOXG1 mRNA was examined by RT-qPCR following transfection of U87 MG with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (D) The expression level of FOXG1 protein was examined by western blot assay following transfection of U87 MG with miR-9-3p mimic and NC mimic (50 pmol/ml) for 48 h. The relative intensity of FOXG1 protein is presented as a bar graph. (E) Relative luciferase activities of FOXG1-wt, and FOXG1-mut were identified using a Dual-Luciferase Reporter assay kit following transfection of TG-905 cells with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (F) The expression level of FOXG1 mRNA was examined by RT-qPCR following transfection of TG-905 cells with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (G) The expression level of FOXG1 protein was examined by western blot assay following transfection of TG-905 cells with miR-9-3p mimic and NC mimic (50 pmol/ml) for 48 h. The relative intensity of FOXG1 protein is presented as a bar graph. *P<0.05, **P<0.01 vs. NC mimic group. FOXG1, forkhead box G1; miR-9-3p, microRNA-9-3p; 3′-UTR, 3′-untranslated region; wt, wild-type; mut, mutant; NC, negative control.

Article Snippet: Cell culture and transfection The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Binding Assay, Luciferase, Reporter Assay, Transfection, Expressing, Quantitative RT-PCR, Western Blot, Mutagenesis, Negative Control

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: miR-9-3p regulates cell proliferation by inhibiting FOXG1. (A and C) Western blotting was used to detect the protein expression of FOXG1 following transfection of U87 MG and TG-905 cells with FOXG1 siRNA (40 pmol/ml) for 48 h. (B and D) Relative cell viability was determined by a Cell Counting Kit-8 assay following transfection of U87 MG and TG-905 cells with FOXG1 (40 pmol/ml) for 24 h. **P<0.01 vs. control group; ##P<0.01 vs. miR-9-3p mimic group; &&P<0.01 vs. FOXG1-siRNA group. FOXG1, forkhead box G1; miR-9-3p, microRNA-9-3p; siRNA, small interfering RNA; control, without any treatment.

Article Snippet: Cell culture and transfection The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Western Blot, Expressing, Transfection, Cell Counting, Small Interfering RNA

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: miR-9-3p regulates cell apoptosis by inhibiting FOXG1. (A) Annexin-V/PI double-staining assay was performed to detect the cell apoptotic rate of U87 MG cells following transfection with FOXG1 siRNA (40 pmol/ml) for 24 h. (B) Annexin-V/PI double-staining assay was applied to detect the cell apoptotic rate of TG-905 cells following transfection with FOXG1 siRNA (40 pmol/ml) for 24 h. **P<0.01 vs. control group; ##P<0.01 vs miR-9-3p mimic group; &&P<0.01 vs. FOXG1-siRNA group. miR-9-3p, microRNA-9-3p; FOXG1, forkhead box G1; PI, propidium iodide; siRNA, small interfering RNA; control, without any treatment.

Article Snippet: Cell culture and transfection The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Double Staining, Transfection, Small Interfering RNA

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: Effects of miR-9-3p overexpression on the proliferation of U87 cells. U87 cells were transfected with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (A and C) RT-qPCR was applied to quantify the expression level of miR-9-3p in U87 MG and TG-905 cells. (B and D) The cell viability of U87 cells was determined by a CCK-8 assay in U87 MG and TG-905 cells. ##P<0.01 vs. NC mimic group. miR-9-3p, microRNA-9-3p; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; NC, negative control; control, without any treatment.

Article Snippet: The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Over Expression, Transfection, Quantitative RT-PCR, Expressing, CCK-8 Assay, Real-time Polymerase Chain Reaction, Negative Control

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: Effects of miR-9-3p overexpression on the apoptosis of U87 cells. U87 cells were transfected with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (A) Annexin-V/PI double-staining assay was applied to detect the cell apoptotic rate in U87 MG cells. (B) Annexin-V/PI double-staining assay was applied to detect the cell apoptotic rate in TG-905 cells. ##P<0.01 vs. NC mimic group. miR-9-3p, microRNA-9-3p; NC, negative control; PI, propidium iodide; control, without any treatment.

Article Snippet: The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Over Expression, Transfection, Double Staining, Negative Control

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: FOXG1 is a direct target of miR-9-3p in glioma cells. (A) Bioinformatics analysis of the predicted interactions of miR-9-3p and its binding sites within the 3′-UTR of FOXG1. (B) Relative luciferase activities of FOXG1-wt, and FOXG1-mut were identified using a Dual-Luciferase Reporter assay kit following transfection of U87 MG with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (C) The expression level of FOXG1 mRNA was examined by RT-qPCR following transfection of U87 MG with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (D) The expression level of FOXG1 protein was examined by western blot assay following transfection of U87 MG with miR-9-3p mimic and NC mimic (50 pmol/ml) for 48 h. The relative intensity of FOXG1 protein is presented as a bar graph. (E) Relative luciferase activities of FOXG1-wt, and FOXG1-mut were identified using a Dual-Luciferase Reporter assay kit following transfection of TG-905 cells with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (F) The expression level of FOXG1 mRNA was examined by RT-qPCR following transfection of TG-905 cells with miR-9-3p mimic and NC mimic (50 pmol/ml) for 24 h. (G) The expression level of FOXG1 protein was examined by western blot assay following transfection of TG-905 cells with miR-9-3p mimic and NC mimic (50 pmol/ml) for 48 h. The relative intensity of FOXG1 protein is presented as a bar graph. *P<0.05, **P<0.01 vs. NC mimic group. FOXG1, forkhead box G1; miR-9-3p, microRNA-9-3p; 3′-UTR, 3′-untranslated region; wt, wild-type; mut, mutant; NC, negative control.

Article Snippet: The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Binding Assay, Luciferase, Reporter Assay, Transfection, Expressing, Quantitative RT-PCR, Western Blot, Mutagenesis, Negative Control

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: miR-9-3p regulates cell proliferation by inhibiting FOXG1. (A and C) Western blotting was used to detect the protein expression of FOXG1 following transfection of U87 MG and TG-905 cells with FOXG1 siRNA (40 pmol/ml) for 48 h. (B and D) Relative cell viability was determined by a Cell Counting Kit-8 assay following transfection of U87 MG and TG-905 cells with FOXG1 (40 pmol/ml) for 24 h. **P<0.01 vs. control group; ##P<0.01 vs. miR-9-3p mimic group; &&P<0.01 vs. FOXG1-siRNA group. FOXG1, forkhead box G1; miR-9-3p, microRNA-9-3p; siRNA, small interfering RNA; control, without any treatment.

Article Snippet: The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Western Blot, Expressing, Transfection, Cell Counting, Small Interfering RNA

Journal: Oncology Letters

Article Title: miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1

doi: 10.3892/ol.2020.11725

Figure Lengend Snippet: miR-9-3p regulates cell apoptosis by inhibiting FOXG1. (A) Annexin-V/PI double-staining assay was performed to detect the cell apoptotic rate of U87 MG cells following transfection with FOXG1 siRNA (40 pmol/ml) for 24 h. (B) Annexin-V/PI double-staining assay was applied to detect the cell apoptotic rate of TG-905 cells following transfection with FOXG1 siRNA (40 pmol/ml) for 24 h. **P<0.01 vs. control group; ##P<0.01 vs miR-9-3p mimic group; &&P<0.01 vs. FOXG1-siRNA group. miR-9-3p, microRNA-9-3p; FOXG1, forkhead box G1; PI, propidium iodide; siRNA, small interfering RNA; control, without any treatment.

Article Snippet: The human glioblastoma U87 MG (CL-0238) and TG-905 (CL-0309) cell lines were purchased from Procell Life Science & Technology Co., Ltd. (the origin of glioblastoma U87 MG cell is unknown and the cell line is preserved at the ATCC).

Techniques: Double Staining, Transfection, Small Interfering RNA